Fundamental Analysis of CHIMERIX INC(NASDAQ:CMRX) stock

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to CMRX. CMRX was compared to 568 industry peers in the Biotechnology industry. CMRX has a great financial health rating, but its profitability evaluates not so good. CMRX is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

CMRX had negative earnings in the past year.

CMRX had a negative operating cash flow in the past year.

In the past 5 years CMRX reported 4 times negative net income.

In the past 5 years CMRX always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CMRX (-52.68%) is comparable to the rest of the industry.

CMRX's Return On Equity of -61.57% is in line compared to the rest of the industry. CMRX outperforms 60.00% of its industry peers.

		Industry Rank	Sector Rank
ROA	-52.68%
ROE	-61.57%
ROIC	N/A

ROA(3y)-49.77%

ROA(5y)-59%

ROE(3y)-76.39%

ROE(5y)-78.16%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of CMRX (203.77%) is better than 99.65% of its industry peers.

CMRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	203.77%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CMRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CMRX has more shares outstanding

The number of shares outstanding for CMRX has been increased compared to 5 years ago.

CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

Based on the Altman-Z score of -2.00, we must say that CMRX is in the distress zone and has some risk of bankruptcy.

CMRX's Altman-Z score of -2.00 is in line compared to the rest of the industry. CMRX outperforms 53.27% of its industry peers.

CMRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2

ROIC/WACCN/A

WACC11.78%

2.3 Liquidity

CMRX has a Current Ratio of 6.33. This indicates that CMRX is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 6.33, CMRX is in the better half of the industry, outperforming 63.36% of the companies in the same industry.

A Quick Ratio of 6.33 indicates that CMRX has no problem at all paying its short term obligations.

CMRX has a Quick ratio of 6.33. This is in the better half of the industry: CMRX outperforms 63.72% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.33
Quick Ratio	6.33

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CMRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.08%.

Looking at the last year, CMRX shows a very negative growth in Revenue. The Revenue has decreased by -85.93% in the last year.

Measured over the past years, CMRX shows a very negative growth in Revenue. The Revenue has been decreasing by -46.25% on average per year.

EPS 1Y (TTM)2.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%3.7%

Revenue 1Y (TTM)-85.93%

Revenue growth 3Y-60.78%

Revenue growth 5Y-46.25%

Sales Q2Q%136.36%

3.2 Future

The Earnings Per Share is expected to grow by 19.35% on average over the next years. This is quite good.

The Revenue is expected to grow by 256.91% on average over the next years. This is a very strong growth

EPS Next Y-10.18%

EPS Next 2Y-7.04%

EPS Next 3Y6.31%

EPS Next 5Y19.35%

Revenue Next Year-38.27%

Revenue Next 2Y134.77%

Revenue Next 3Y349.84%

Revenue Next 5Y256.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMRX. In the last year negative earnings were reported.

Also next year CMRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-7.04%

EPS Next 3Y6.31%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for CMRX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CHIMERIX INC

NASDAQ:CMRX (12/18/2024, 3:47:06 PM)

2.7107

-0.1 (-3.53%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap243.80M

Analysts

Price Target

Short Float %

Short Ratio

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-52.68%
ROE	-61.57%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	203.77%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.33
Quick Ratio	6.33
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)2.08%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-10.18%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-85.93%

Revenue growth 3Y-60.78%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

CHIMERIX INC (CMRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens